Aeglea BioTherapeutics, Inc. (AGLE): Price and Financial Metrics

Aeglea BioTherapeutics, Inc. (AGLE): $12.01

0.97 (+8.79%)

POWR Rating

Component Grades

Momentum

D

Stability

F

Sentiment

Quality

D

Add AGLE to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#246 of 339

in industry

AGLE Price/Volume Stats

Current price $12.01 52-week high $32.75
Prev. close $11.04 52-week low $2.66
Day low $10.69 Volume 43,300
Day high $12.34 Avg. volume 95,409
50-day MA $11.42 Dividend yield N/A
200-day MA $9.59 Market Cap 48.63M

AGLE Stock Price Chart Interactive Chart >


Aeglea BioTherapeutics, Inc. (AGLE) Company Bio


Aeglea Biotherapeutics, Inc., a biopharmaceutical company, engages in developing engineered human enzymes for the treatment of inborn errors of metabolism and cancer. The company was founded in 2013 and is based in Austin, Texas.


AGLE Latest News Stream


Event/Time News Detail
Loading, please wait...

AGLE Latest Social Stream


Loading social stream, please wait...

View Full AGLE Social Stream

Latest AGLE News From Around the Web

Below are the latest news stories about AEGLEA BIOTHERAPEUTICS INC that investors may wish to consider to help them evaluate AGLE as an investment opportunity.

Aeglea BioTherapeutics Announces Grants of Inducement Awards

Aeglea BioTherapeutics, Inc. ("Aeglea") (NASDAQ: AGLE), a biotechnology company advancing a pipeline of antibody therapeutics with the potential to transform the treatment of inflammatory bowel disease ("IBD"), today announced that Aeglea's independent Compensation Committee of the Board of Directors approved the grants of stock options to purchase an aggregate of 351,750 shares of common stock and a grant of 18,912 restricted stock units to four non-executive employees as equity inducement awar

Yahoo | November 22, 2023

Aeglea BioTherapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Aeglea BioTherapeutics, Inc. ("Aeglea" or the "Company") (NASDAQ:AGLE), a biotechnology company advancing a pipeline of antibody therapeutics with the potential to transform the treatment of inflammatory bowel disease ("IBD"), today announced its third quarter 2023 financial results and provided program and corporate updates.

Yahoo | November 9, 2023

Aeglea BioTherapeutics to Participate in Upcoming November Investor Conferences

Aeglea BioTherapeutics, Inc. ("Aeglea") (Nasdaq: AGLE), a biotechnology company advancing a pipeline of antibody therapeutics with the potential to transform the treatment of inflammatory bowel disease ("IBD"), today announced that management will participate in the following investor conferences:

Yahoo | October 31, 2023

Aeglea BioTherapeutics to Participate in Upcoming September Conference

Aeglea BioTherapeutics, Inc. ("Aeglea") (Nasdaq: AGLE), a biotechnology company advancing a pipeline of antibody therapeutics with the potential to transform the treatment of inflammatory bowel disease ("IBD"), today announced that management will participate in the Stifel 2023 Immunology & Inflammation Virtual Summit.

Yahoo | September 14, 2023

Aeglea BioTherapeutics Announces Reverse Stock Split

Aeglea BioTherapeutics, Inc. ("Aeglea") (Nasdaq: AGLE), a biotechnology company advancing a pipeline of antibody therapeutics with the potential to transform the treatment of inflammatory bowel disease ("IBD"), today announced it will effect a reverse stock split of all outstanding shares of Aeglea's common stock at a ratio of 1-for-25. Aeglea expects its common stock to begin trading on a split-adjusted basis on the Nasdaq Capital Market as of the commencement of trading on September 8, 2023.

Yahoo | September 7, 2023

Read More 'AGLE' Stories Here

AGLE Price Returns

1-mo N/A
3-mo N/A
6-mo N/A
1-year 20.10%
3-year -93.19%
5-year -92.37%
YTD N/A
2023 0.00%
2022 -90.53%
2021 -39.64%
2020 3.01%
2019 2.00%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!